Ultime notizie per Robinhood Markets (NASDAQ:HOOD) Azioni

ROBINHOOD MARKETS INC - A

Robinhood Markets

Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fraud detection, derivatives, fractional shares, recurring investments, and others.

Robinhood,,An,Online,Investing,Platform,,Mobile,App,Displayed,On,The

Equities

News

Markets

HOOD

La piattaforma di trading amplia i servizi finanziari. Conti correnti, risparmi e strumenti innovativi per gli investitori. Scopriamo di più.

Robinhood lancia Robinhood Banking: rendimento al 4% e consigli dall&#39;AI

Cathie Wood's Wednesday Moves: Ark Pours $1.36 Million Into Tempus AI Shares Following Deep 6 AI Acquisition, Offloads Rocket Lab Stock

ETFs

General

$BTC

ARKK

COIN

Giovedì Ark Invest di Cathie Wood ha effettuato importanti operazioni, concentrandosi sull’acquisizione di azioni di Robinhood Markets Inc (NASDAQ:HOOD), Coinbase Global Inc (NASDAQ:C

Ark Invest guidata da Cathie Wood sfida il mercato ribassista e investe qui

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

ARKF

ARKQ

ARKW

ARKX

PLTR

TSLA

Lunedì Ark Invest di Cathie Wood ha effettuato importanti operazioni su Tesla Inc. (NASDAQ:TSLA), Palantir Technologies Inc. (NASDAQ:PLTR), Coinbase Global Inc. (NASDAQ

Cathie Wood fa shopping durante il crollo? Ecco cosa ha acquistato Ark Invest

Robinhood Markets, Inc. - Class A Common Stock

Robinhood Markets Inc

Stifel analyst W. Andrew Carter maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Buy and lowers the price target from $500 to $450.

Price Target

Analyst Ratings

Stifel Maintains Buy on RH, Lowers Price Target to $450

Monro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNRO#NASDAQ">MNRO</a>), a leading provider of automotive undercar repair and tire services, today announced the appointment of Peter Fitzsimmons, Partner and Managing Director of AlixPartners, as President and Chief Executive Officer, effective immediately. Michael Broderick has departed the Company as President and CEO following the Board's determination that a change in leadership is necessary.
Fitzsimmons' mandate is to work with the management team and Board to develop and execute a performance improvement plan to enhance operations, drive profitability, and increase operating income and total shareholder returns.
During his career, Fitzsimmons has served in senior executive roles at clients undertaking significant efforts to improve operations and financial performance. Some of his notable executive experience includes serving as CEO of a large automotive collision repair business, where he drove an over 25% sales improvement in 2022, and as CFO of an auto parts distributor.
Chairman of the Board, Robert Mellor said, "The Monro Board and management are taking decisive actions intended to improve the Company's performance and enhance the value we are delivering to our shareholders today, and over the long-term. As part of this, the Board determined that a change in leadership was necessary, and we are pleased to appoint Peter to lead this critical phase in our evolution, and our next chapter of growth. Peter has a proven track record of success and a mandate to reinvigorate the business and restore operating margins. We are confident that with our consistent cash generation, ample liquidity, solid balance sheet, and our compelling offerings to customers, Monro will achieve its potential as a premier automotive service provider under Peter's leadership."
Fitzsimmons said, "Monro has shown impressive durability through business cycles and benefits from a low leverage profile, nation-wide presence and important strategic relationships. I look forward to working with the Board and management team to improve Monro's performance and unlock its full value."
Mellor continued, "We appreciate Mike Broderick's commitment to Monro and thank him for his contributions. We wish him all the best."
Fitzsimmons has been appointed as President and CEO in connection with, and as part of a strategic consulting engagement with AlixPartners, LLP and its affiliate AP Services, LLC.

Management

MNRO

Monro Appoints New CEO Peter Fitzsimmons, Ousting Michael Broderick to Boost Performance

Edible Garden AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) reported quarterly losses of $(10.34) per share which missed the analyst consensus estimate of $(9.00) by 14.89 percent. This is a 96.17 percent increase over losses of $(270.00) per share from the same period last year. The company reported quarterly sales of $3.87 million which missed the analyst consensus estimate of $4.13 million by 6.13 percent. This is a 5.56 percent decrease over sales of $4.10 million the same period last year.

Earnings

Earnings Misses

EDBL

Edible Garden AG GAAP Q4 EPS $(10.34) Misses $(9.00) Estimate, Sales $3.87M Miss $4.13M Estimate

Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $300 to $345.

ALNY

Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $345

Canaccord Genuity analyst Joseph Vafi maintains Galaxy Digital Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>) with a Buy and raises the price target from C$36 to C$37.

TSX:GLXY

Canaccord Genuity Maintains Buy on Galaxy Digital Hldgs, Raises Price Target to C$37

Edible Garden AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) reported quarterly losses of $(10.34) per share which missed the analyst consensus estimate of $(9.00) by 14.89 percent. &nbsp;The company reported quarterly sales of $3.87 million which missed the analyst consensus estimate of $4.13 million by 6.13 percent. This is a 5.56 percent decrease over sales of $4.10 million the same period last year.

Edible Garden AG Q4 2024 GAAP EPS $(10.34) Misses $(9.00) Estimate, Sales $3.87M Miss $4.13M Estimate

Star Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STHO#NASDAQ">STHO</a>) (the "Company") announced the following:
<a href="https://mma.prnewswire.com/media/2039485/Star_Holdings_Logo.html"><img src="https://mma.prnewswire.com/media/2039485/Star_Holdings_Logo.jpg" alt="Star Holdings Logo (PRNewsfoto/iStar Inc.)" /></a>
Share Repurchase Program
The Company's Board of Trustees has authorized the repurchase of up to&nbsp;$10 million of the Company's common shares. These repurchases may be made from time to time in the open market, in privately negotiated transactions, or otherwise, including pursuant to a Rule 10b5-1 plan, subject to market and pricing conditions, applicable law and other factors deemed relevant in the Company's sole discretion. The share repurchase authorization does not obligate the Company to repurchase any dollar amount or number of shares, and may be suspended or discontinued at any time.
Term Loan Credit Agreement with Safehold
The Term Loan Credit Agreement has been amended to, among other things:
<ul>
<li>Extend the maturity date of the underlying term loan facilities by one year, to March 31, 2028</li>
<li>Provide that Star Holdings may re-borrow amounts that have been paid on the $25 million incremental facility available under the agreement for permitted purposes</li>
<li>Provide a restricted payments basket that will permit the Company to repurchase up to $10 million of its common shares for cash</li>
</ul>
As of March 28, 2025, the outstanding term loan had a principal balance of $115.0 million and no outstanding borrowings on the incremental facility.
Management Agreement with Safehold
The Management Agreement has been amended to, among other things:
<ul>
<li>Increase the management fee payable in respect of the annual term running from April 1, 2026 through March 31, 2027 from $5.0 million to $7.5 million</li>
<li>Increase the "Termination Fee" payable to the manager in certain circumstances from $50.0 million to $55.0 million, in each case less the aggregate amount of management fees paid prior to the termination date</li>
</ul>
Amendment to Margin Loan Facility
The Margin Loan Facility has been amended to, among other things:
<ul>
<li>Extend the maturity date of the underlying margin loan facility by two years, to March 31, 2028</li>
<li>Provide a commitment for up to $15.8 million of additional funding on a delayed-draw basis, subject to satisfaction of the conditions for drawing</li>
<li>Provide for increases in the applicable margin</li>
<li>Improve certain loan-to-value ratios and collateral release thresholds</li>
</ul>

Buybacks

SAFE

STHO

Star Holdings Approves $10M Share Buyback and Extends Key Loan Agreements

Edible Garden Continues To Pursue Strategic Narayan Acquisition

LGND

Ligand Pharmaceuticals FY 2024 GAAP EPS $(7.83) Misses $2.10 Estimate, Cash Balance Of $83.6M Expected To Fund Operations Into The Second Half Of 2027

Regulatory Timelines
The Company initiated regulatory correspondence with the US Food &amp; Drug Administration (FDA) and the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) in the first quarter of 2025. The Company intends to initiate regulatory interaction with the European Medicines Agency (EMA) and EMA National Competent Authorities in the second quarter of 2025.
FDA
<ul>
<li>Q1/25: Regulatory communication regarding endpoints for accelerated approval</li>
<li>Q2/25: End of Phase 2 Meeting</li>
<li>Q3/25: Initiation of rolling BLA submission</li>
<li>Q4/25: Conditional BLA via Accelerated Approval Program</li>
</ul>
MHRA
<ul>
<li>Q1/25: Scientific Advice Meeting requested and granted</li>
<li>Q3/25: Scientific Advice Meeting with MHRA and ILAP application submission</li>
<li>Q4/25: Application for joint Scientific Advice Meeting with MHRA and National Institute for Health and Care Excellence (NICE)</li>
<li>Q4 25: MHRA Conditional Marketing Authorisation application.</li>
</ul>
EMA
<ul>
<li>Q2/25: EMA National Competent Authority Scientific Advice Meeting Request (Medicines Evaluation Board, Netherlands)</li>
<li>Q3/25: EMA PRIME and EMA Orphan Designation applications</li>
<li>Q4/25: EMA-FDA Parallel Scientific Advice application</li>
<li>Q1 26: EMA Conditional Marketing Authorisation application.</li>
</ul>
The Company has recently buttressed its regulatory and clinical strategy &amp; operations infrastructure with the addition of key consulting agencies with significant track records in rare pediatric cancer, Priority Review Voucher (PRV) program approvals, and worldwide Conditional Market Access Applications including in the EU and UK.
The Company reiterates its commitment to seeking to obtain FDA approval for OST-HER2 in the rare pediatric cancer osteosarcoma in 2025. The Company is eligible to receive a Priority Review Voucher (PRV) if OST-HER2 is approved under its Rare Pediatric Disease Designation (RPDD) by September 30, 2026.
The Company has sufficient cash on hand to operate into 2026.

Health Care

OSTX

OS Therapies Provided A Regulatory Update For Its OST-HER2 Listeria Monocytogenes Immunotherapeutic Cancer Biologic Drug Candidate To Prevent Or Delay Fully-Resected, Recurrent, Lung Metastatic Osteosarcoma

Piper Sandler analyst Alexander Goldfarb maintains Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) with a Underweight and lowers the price target from $60 to $55.

IIPR

Piper Sandler Maintains Underweight on Innovative Ind Props, Lowers Price Target to $55

APi Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) ("APi" or the "Company") today announced the appointment of David Jackola as Executive Vice President &amp; Chief Financial Officer, effective immediately. Mr. Jackola has been with the Company since October 2021, most recently serving as Interim Chief Financial Officer since December of 2024. He will report directly to Russ Becker, President and Chief Executive Officer of APi. Russ Becker, APi's President and Chief Executive Officer stated: "David is a great leader and has a proven track record of driving profitable organic growth and executing on our strategic objectives. After a comprehensive process, the Board and I agreed that David is the ideal candidate to serve as APi Group's next Chief Financial Officer. He brings a unique combination of financial acumen and global experience together with a deep understanding of our business and strong, established relationships with our leaders around the world. I have full confidence that David will continue to be a strong leader for APi, our teammates, and our shareholders as we return to more traditional levels of organic growth in 2025 and beyond." David Jackola, APi's Executive Vice President and Chief Financial Officer stated: "I am excited and humbled to be chosen as APi's next CFO. I'm grateful for the team's confidence in me. I look forward to leading the talented team of global finance and IT professionals at APi, supporting our field leaders, living our enduring purpose of Building Great Leaders, and helping APi achieve its long-term strategic objectives." Mr. Jackola brings more than 20 years of global finance experience to the role. Prior to his role as Interim CFO, he served as Chief Financial Officer and Vice President of Transformation at APi International. Prior to that role, he was Vice President, Controller and Chief Accounting Officer at APi. He began his career at APi as Vice President, Corporate Planning and Analysis. Prior to joining APi, Mr. Jackola served in senior finance roles at both James Hardie Building Products, where he served as head of finance for North America, and Ecolab, where he served as Vice President of Finance, Europe and in other various senior finance roles. Mr. Jackola will be joining Mr. Becker and other senior leaders at APi's Investor Day on May 21 in New York and will be discussing the Company's positive momentum through the first half of the year as well as presenting updated long-term strategic objectives.

APi Group Names David Jackola as New CFO After Successful Interim Run

Piper Sandler analyst Korinne Wolfmeyer maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Overweight and lowers the price target from $102 to $90.

Piper Sandler Maintains Overweight on e.l.f. Beauty, Lowers Price Target to $90

Biotech

Guidance

MAZE

Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027

Chester Xie, the Company's current financial controller, has been appointed interim CFO.

NEWP

New Pacific Metals Says Andrew Williams Will Be Stepping Down As CEO And Director, Effective April 15; Names Current CFO Jalen Yuan As Interim CEO

GeoPark Limited ("GeoPark" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>), a leading independent energy company with over 20 years of successful operations across Latin America, today announced divestments of certain non-core assets and cost reduction initiatives to better position the Company for profitable, dependable and sustainable long-term growth.
In line with its commitment to disciplined capital allocation, the Company will divest the non-core, non-operated Llanos 32 Block in Colombia and Manati gas field in Brazil for an aggregate total consideration of $20 million1 (net of $12 million liabilities related to decommissioning or retirement obligations, with respect to the Manati gas field). Combined, these assets had aggregate net 1P PRMS reserves of 2.9 mmboe (60% oil, 40% natural gas) at 2024 year-end and an average production of 712 boepd in 2024. Together, the assets represented approximately 1,500 boepd in the 2025 plan, with an associated adjusted EBITDA2 of $10-13 million at $70-80/bbl Brent.
Furthermore, GeoPark is evaluating strategic options for its assets in Ecuador.
In addition to the timely monetization of the above non-core assets, GeoPark is currently implementing targeted cost reduction and cost efficiency measures that the Company expects will deliver annual savings of approximately $5-7 million in OPEX/G&amp;A costs. These initiatives include immediate adjustments to structure costs, including reductions in our workforce and to consultants, contractors, and other administrative expenses.

Asset Sales

GPRK

GeoPark Sells Non-Core Oil and Gas Assets in Colombia and Brazil for $20M

Piper Sandler analyst Korinne Wolfmeyer maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $108 to $107.

Piper Sandler Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $107

Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD $1 million.&nbsp;
In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics. Having decided not to pursue development of Cantrixil in ovarian cancer, as originally anticipated under the license, Vivesto is currently exploring Cantrixil preclinically for the treatment of hematological cancers. Cantrixil, a legacy molecule in the Kazia pipeline, is a product candidate consisting of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in α-cyclodextrin.
"We are pleased to enter into this agreement with Vivesto, which provides a source of non-dilutive funding that will help advance our proprietary, clinical-stage pipeline," said John Friend, M.D., Chief Executive Officer of Kazia Therapeutics.&nbsp;

KZIA

Kazia Sells Rights to Legacy Cancer Drug Cantrixil for $1M to Fund New Research

The Company reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide and highlighted next steps in its obesity program for its novel next-generation MC4R long-acting peptides and oral small molecules.

Palatin Technologies Says BMT-801 Phase 2 Obesity Co-administration Study Met Its Primary Endpoint And Was Highly Statistically Significant

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and maintains $25 price target.

HUMA

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Fintech

Press Releases

CQG to Provide Order Routing Infrastructure for all Robinhood Futures Trades

Robinhood Markets, Inc. Reports February 2025 Operating Data

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Robinhood Markets, Inc. - HOOD

Legal

ROBINHOOD ALERT: Bragar Eagel & Squire, P.C. is Investigating RobinHood Markets, Inc. on Behalf of RobinHood Stockholders and Encourages Investors to Contact the Firm

Defiance Launches HOOX: 2X Leveraged ETF for Robinhood Markets, Inc.

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Flywire, Civitas, and SoundHound and Encourages Investors to Contact the Firm

CIVI

FLYW

SOUN

BGC Group

Evercore

Freedom Holding

Futu Holdings Limited - American Depositary Shares

Futu Hldgs

Goldman Sachs Group, Inc. (The) Common Stock

Goldman Sachs Group

Houlihan Lokey, Inc. Class A Common Stock

Houlihan Lokey

Interactive Brokers Group, Inc. - Class A Common Stock

Interactive Brokers Group

Jefferies Financial Group Inc. Common Stock

Jefferies Financial Gr

Lazard

LPL Financial Holdings Inc. - Common Stock

LPL Finl Hldgs

Moelis

Marex Group

Morgan Stanley

Nomura Holdings Inc ADR American Depositary Shares

Nomura Holdings

Oppenheimer Holdings, Inc. Class A Common Stock (DE)

Oppenheimer Hldgs

Piper Sandler

PJT Partners

Perella Weinberg Partners - Class A Common Stock

Perella Weinberg

Raymond James Financial, Inc. Common Stock

Raymond James Finl

Charles Schwab Corporation (The) Common Stock

Charles Schwab

Stifel Financial Corporation Common Stock

Stifel Financial

StoneX Group

UP Fintech Holding Limited - American Depositary Shares representing fifteen Class A Ordinary Shares

UP Fintech Holding

Virtu Financial, Inc. - Class A Common Stock

Virtu Finl

Citizens Capital Markets

Needham

Keefe, Bruyette & Woods

Compass Point

Deutsche Bank

Screenshot 2025-03-24 at 5.42.31 PM

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

BTCS

BTCS Reports Record Revenue Growth For 2024 Driven By Focus On Ethereum Block Building

Screenshot 2025-02-26 at 6.30.39 PM

Options

CBOE

Cboe Democratizes Volatility Products For Retail Traders

Screenshot 2024-12-16 at 6.50.17 PM

Interest in Index Options Continue to Grow–Find Out Why

Screenshot 2024-11-15 at 8.03.57 PM

Fintech news covering the emerging Financial Technology services sector

Comments

Robinhood Markets

Notizie

Ultime notizie per Robinhood Markets (NASDAQ:HOOD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO